Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma

ABSTRACT: The median survival time of patients with glioblastoma is 14-16 months with a 5-year overall survival rate of 9.8%. Standard of care treatment includes radiation with concomitant temozolomide followed by cyclic temozolomide. If the patient develops myelosuppression (thrombocytopenia, leukopenia or anemia), the dose of temozolomide is reduced or stopped to avoid bleeding or infections. Recent studies have demonstrated that mild leukopenia is associated with increased overall survival in patients with glioblastoma. To confirm prior results showing that leukopenia is associated with increased overall survival as a primary outcome in patients with glioblastoma, the present study retrospectively collected complete blood counts from 141 patients with glioblastoma treated at the Beth Israel Deaco

SUBMITTER: Ho K 

PROVIDER: S-EPMC7549395 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature